Cargando…

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study

INTRODUCTION: Baricitinib, a JAK1/JAK2 inhibitor, is approved for treatment of moderate-to-severe rheumatoid arthritis (RA) in China. This single-arm, prospective, multi-center, post-marketing safety study (PMSS) evaluated the safety and effectiveness of baricitinib in Chinese patients. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chan-yuan, Wang, Qian, Shi, Jian, Zhang, Xiu-ying, Du, Rong, Gu, Jie-ruo, Liu, Qi-huan, Yu, Jiao, Xu, Jia-wei, Zhang, Yan-jie, Zhu, Hao, Li, Meng-tao, Zeng, Xiao-feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654295/ https://www.ncbi.nlm.nih.gov/pubmed/37768505 http://dx.doi.org/10.1007/s40744-023-00596-4

Ejemplares similares

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
por: Yang, Yue, et al.
Publicado: (2020)

Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A Bayesian network meta-analysis
por: Haikun, Wang, et al.
Publicado: (2022)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2017)

Baricitinib exposure during pregnancy in rheumatoid arthritis
por: Costanzo, Giulia, et al.
Publicado: (2020)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
por: Thudium, Christian S., et al.
Publicado: (2020)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
por: Kawalec, Paweł, et al.
Publicado: (2019)

Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

The beneficial effect of baricitinib on ultrasound-detected synovial inflammation and bone damage in rheumatoid arthritis: Preliminarily data from single center-based observational study for 24 weeks
por: Kim, Seong-Kyu, et al.
Publicado: (2021)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
por: Koumaki, Dimitra, et al.
Publicado: (2019)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
por: Combe, Bernard, et al.
Publicado: (2019)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ren, Shijie, et al.
Publicado: (2018)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
por: Smolen, Josef S, et al.
Publicado: (2020)

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
por: Hernández-Cruz, Blanca, et al.
Publicado: (2023)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2023)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes
por: Tucci, Gloria, et al.
Publicado: (2022)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
por: Faria, Sofia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g7kgv99kl6be2i8e8pn3lpn2nu